Organisation paid for research Program year 2025 Source: CMS Open Payments

Avantis Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$2,138,619

162 payments

Through program year 2025, Avantis Clinical Research LLC is reported as receiving $2,138,619 in research payments, across 162 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$49,119	5
2024	Research	$265,727	39
2023	Research	$1,096,003	98
2022	Research	$727,770	20

Breakdown

Who paid Research payments · program years 2022–2025

Organon LLC $1,672,823 58 payments
Supernus Pharmaceuticals, Inc. $216,889 9 payments
GlaxoSmithKline, LLC. $129,614 21 payments
Biohaven Pharmaceutical Holding Company Ltd. $64,148 60 payments
Genentech, Inc. $55,145 14 payments

Studies the money was for Research payments · program years 2022–2025

Og-8175A-023 $907,572 11 payments
Og-8175A-023 $765,251 47 payments
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults With Treatment Resistant Depression $216,889 9 payments
A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Cont $101,649 18 payments
A Phase 23 Doubleblind Randomized Placebocontrolled Safety and Efficacy Trial of Bhv3000 Rimegepant Orally Disintegrating Tablet Odt for the Acute Treatment of Chronic Rhinosinusitis CRS With Or Without Nasal Polyps $64,148 60 payments
PH III Study to Evaluate the Efficacy and Safety of Astegolimab in COPD $47,145 13 payments
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multic $27,965 3 payments
Ph III OLE of Astegolimab in COPD $8,000 1 payment

What the money was spent on Research payments · program years 2022–2025

Patient care $1,672,823 58 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.